FN2 Earnings Intelligence

Jazz Pharmaceuticals plc earnings overview

Latest Jazz Pharmaceuticals plc (JAZZ) earnings intelligence, including the newest scorecard, market reaction, and transcript analysis.

Next reportJazz Pharmaceuticals plc reports Tuesday, Feb 23, 2027 · After market closeConsensus EPS $6.52 · consensus revenue $1.24B
JAZZ FY2026 Q3 · Calendar Q4 2026

Jazz Pharmaceuticals plc

The quarter strengthens the case that Jazz’s commercial portfolio can support growth: record revenue, continuing Xywav expansion and Ziihera’s early launch accompanied a higher 2026 revenue outlook. The durability of that trajectory depends on execution across new oncology uptake and established products facing competition.

EPS surprise+4.2%
Market move-0.7%

Get the JAZZ recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.